因子XI/XIa抑制剂预防和治疗静脉和动脉血栓栓塞症：叙述性综述。

IF 3 3区医学 Q2 PERIPHERAL VASCULAR DISEASE

Vascular Medicine Pub Date : 2024-02-01 Epub Date: 2023-11-10 DOI:10.1177/1358863X231206778

Swathi Prakash, Adriana C Mares, Mateo Porres-Aguilar, Debabrata Mukherjee, Geoffrey D Barnes

{"title":"因子XI/XIa抑制剂预防和治疗静脉和动脉血栓栓塞症：叙述性综述。","authors":"Swathi Prakash, Adriana C Mares, Mateo Porres-Aguilar, Debabrata Mukherjee, Geoffrey D Barnes","doi":"10.1177/1358863X231206778","DOIUrl":null,"url":null,"abstract":"During the past decade, direct oral anticoagulants (DOACs) have advanced and simplified the prevention and treatment of venous thromboembolism (VTE). However, there remains a high incidence of bleeds, which calls for agents that have a reduced risk of bleeding. Factor XI (FXI) deficiency is associated with lower rates of venous thrombosis and stroke compared to the general population with a lower risk of bleeding. In conjunction with this, phase 2 studies have demonstrated safety and the potential for reduced thrombotic events with FXI inhibitors as compared to currently available medications. The aim of this review is to summarize key data on the clinical pharmacology of FXI, the latest developments in clinical trials of FXI inhibitors, and to describe the efficacy and safety profiles of FXI inhibitors for the prevention of venous and arterial thromboembolism.","PeriodicalId":23604,"journal":{"name":"Vascular Medicine","volume":null,"pages":null},"PeriodicalIF":3.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review.\",\"authors\":\"Swathi Prakash, Adriana C Mares, Mateo Porres-Aguilar, Debabrata Mukherjee, Geoffrey D Barnes\",\"doi\":\"10.1177/1358863X231206778\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"During the past decade, direct oral anticoagulants (DOACs) have advanced and simplified the prevention and treatment of venous thromboembolism (VTE). However, there remains a high incidence of bleeds, which calls for agents that have a reduced risk of bleeding. Factor XI (FXI) deficiency is associated with lower rates of venous thrombosis and stroke compared to the general population with a lower risk of bleeding. In conjunction with this, phase 2 studies have demonstrated safety and the potential for reduced thrombotic events with FXI inhibitors as compared to currently available medications. The aim of this review is to summarize key data on the clinical pharmacology of FXI, the latest developments in clinical trials of FXI inhibitors, and to describe the efficacy and safety profiles of FXI inhibitors for the prevention of venous and arterial thromboembolism.\",\"PeriodicalId\":23604,\"journal\":{\"name\":\"Vascular Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vascular Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/1358863X231206778\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/11/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/1358863X231206778","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/11/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

摘要

在过去的十年里，直接口服抗凝血剂（DOAC）促进并简化了静脉血栓栓塞症（VTE）的预防和治疗。然而，出血的发生率仍然很高，这就需要降低出血风险的药物。与出血风险较低的普通人群相比，因子XI（FXI）缺乏与静脉血栓形成和中风的发生率较低有关。同时，2期研究已经证明，与目前可用的药物相比，FXI抑制剂的安全性和减少血栓事件的潜力。本综述的目的是总结FXI临床药理学的关键数据、FXI抑制剂临床试验的最新进展，并描述FXI抑制剂预防静脉和动脉血栓栓塞的疗效和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Factor XI/XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism: A narrative review.

During the past decade, direct oral anticoagulants (DOACs) have advanced and simplified the prevention and treatment of venous thromboembolism (VTE). However, there remains a high incidence of bleeds, which calls for agents that have a reduced risk of bleeding. Factor XI (FXI) deficiency is associated with lower rates of venous thrombosis and stroke compared to the general population with a lower risk of bleeding. In conjunction with this, phase 2 studies have demonstrated safety and the potential for reduced thrombotic events with FXI inhibitors as compared to currently available medications. The aim of this review is to summarize key data on the clinical pharmacology of FXI, the latest developments in clinical trials of FXI inhibitors, and to describe the efficacy and safety profiles of FXI inhibitors for the prevention of venous and arterial thromboembolism.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Vascular Medicine 医学-外周血管病

CiteScore

5.70

自引率

5.70%

发文量

158

审稿时长

>12 weeks

期刊介绍： The premier, ISI-ranked journal of vascular medicine. Integrates the latest research in vascular biology with advancements for the practice of vascular medicine and vascular surgery. It features original research and reviews on vascular biology, epidemiology, diagnosis, medical treatment and interventions for vascular disease. A member of the Committee on Publication Ethics (COPE)